Jan Meulen

Company: Obsidian Therapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion – Engineering Matters to Counter the Tumor Microenvironment (TME) for Better Persistence 11:30 am

Modifications to achieve blockade of checkpoints (e.g., PD1 KO) or other ligand signalling (e.g., TGFbeta dominant negative) ‘Armouring’ cells with membrane-bound or secreted cytokines Modulation of TME itself to increase tumor ‘warmth’ Dual- and multi-targeting to prevent antigen escape Increasing the safety of therapies by adding ‘switches’ to turn on/off expression of required mattersRead more

day: Day One